tratamiento ortodoncico en pacientes con diabets mellitus Diabetes Mellitus
Gliclazide MR in the management of Type 2 Diabetes Mellitus
-
Upload
endocrinology-department-bsmmu -
Category
Health & Medicine
-
view
2.517 -
download
3
description
Transcript of Gliclazide MR in the management of Type 2 Diabetes Mellitus
![Page 1: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/1.jpg)
GLICLAZIDE MR IN THE MANAGEMENT OF TYPE 2 DM
Dr. Nazma AkhtarResident phase B
Department of EndocrinologyBSMMU
![Page 2: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/2.jpg)
![Page 3: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/3.jpg)
3/28/2013 3
![Page 4: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/4.jpg)
3/28/2013 4
![Page 5: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/5.jpg)
SULFONYLUREA: OAD agent
Mode of action:• Sulfonylureas act directly on the β - cells of the islets of Langerhans
to stimulate insulin secretion • They enter the β – cell and bind to the cytosolic surface of the
sulfonylurea receptor 1• Binding of a sulfonylurea closes the K + ATP channel, reducing the
efflux of potassium enabling membrane depolarization• Localized membrane depolarization opens adjacent voltage -
dependent L - type calcium channels • Increasing calcium influx and raising the cytosolic free calcium
concentration• Mediate the exocytotic release of insulin granules
![Page 6: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/6.jpg)
![Page 7: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/7.jpg)
Classification
• Divided into first and second generation agents
• In general, the second-generation agents – Are more potent – Have fewer adverse effects and drug-drug
interactions
![Page 8: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/8.jpg)
Extended release preparations
• Extended-release glipizide and glimepiride are preferred agents because
- they can be given once daily - involve a relatively low risk of
hypoglycemia -low weight gain
![Page 9: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/9.jpg)
Modified release preparations
• A “ modified release ” (MR) formulation of gliclazide has been introduced for once - daily dosing
• Interestingly, the 30 mg preparation of gliclazide MR gives similar efficacy to 80 mg of unmodified gliclazide and reduces risk of severe hypoglycemia
![Page 10: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/10.jpg)
![Page 11: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/11.jpg)
Þ Target HbA1c <7% instead of <6.5%
Þ Evidence based alternative approach
Þ SU as 1st line, irrespective of BMI
Þ TZD & DPP-4 inhibitor are 3rd option
What’s NEW in the treatmentalgorithm of IDF Guideline 2012?
![Page 12: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/12.jpg)
Which SU to choose-gliclazide 80, glimepiride or the new Diamicron MR 60?
?
![Page 13: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/13.jpg)
One of the largest clinical studiesever performed in type 2 diabetes
N Engl J Med. 2008;358:2560-2572
![Page 14: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/14.jpg)
More than 11,000 type 2 diabetic patients from 20 countries worldwide
4 Asian countries- China, India, Malaysia & Philippines
N Engl J Med. 2008;358:2560-2572
![Page 15: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/15.jpg)
Aim of the study
What benefits can be gained from intensive glycemic control (HbA1c ≤6.5%) versus standard control?
N Engl J Med. 2008;358:2560-2572
![Page 16: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/16.jpg)
Strategy & Timeline
Mean duration 5 years
Strategy: treatment initiation with 60 mg Diamicron MR, increase up to 120 mg then
add other therapyJune 2001
January 2002
January 2003
January 2004
January 2005
January 2006
January 2007
January 2008
Blood glucose lowering comparisonRecruitment period
N Engl J Med. 2008;358:2560-2572
![Page 17: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/17.jpg)
Results & Outcomes
N Engl J Med. 2008;358:2560-2572. Diabetes Care 32:2068–2074, 2009. Diabetes Res Clin Pract. 2010;89:126-133.
![Page 18: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/18.jpg)
Reduces HbA1c ≤7% within 6 months
N Engl J Med. 2008;358:2560-2572
![Page 19: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/19.jpg)
Reduces HbA1c by more than 4%unlike other SU
N Engl J Med. 2008;358:2560-2572
![Page 20: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/20.jpg)
Reduces HbA1c ≤7% irrespective of BMI
N Engl J Med. 2008;358:2560-2572
![Page 21: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/21.jpg)
Lowest episodes of hypoglycemiacompared to other large scale clinical trials
1. N Engl J Med. 2008;358:2560-2572. 2. N Engl J Med. 2008;358:2545-2559. 3. Lancet. 1998;352:837-853.
![Page 22: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/22.jpg)
Lowest hypoglycemiacompared to DPP4-inhibitor
Int J Clin Pract. 2011;65:1132-1140. Curr Med Res Opin 2012; 28:1–8
Middle East
India & Malaysia
MORE
EVIDENCESMORE
EVIDENCES
![Page 23: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/23.jpg)
Weight neutral unlike other SU
N Engl J Med. 2008;358:2560-2572
5 YEARS
DATA5 YEARS
DATA
![Page 24: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/24.jpg)
Significantly reduces combinedmicro & macro vascular complications
N Engl J Med. 2008;358:2560-2572
![Page 25: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/25.jpg)
Opposite outcome compared to other trials using glimepiride
N Engl J Med. 2008;358:2545-2559. N Engl J Med. 2008;358:2560-2572. N Engl J Med. 2009;360.
MORE
EVIDENCESMORE
EVIDENCES
![Page 26: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/26.jpg)
Better CV protectionthan Metformin & glimepiride
Eur Heart J. 2011 Aug;32(15):1900-8.
MORE
EVIDENCESMORE
EVIDENCES
![Page 27: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/27.jpg)
Reduces End-stage Kidney Diseaseunlike any other OAD
Diabetologia. 2011;54(suppl 1):S23.
RECENT
ANALYSISRECENT
ANALYSIS
![Page 28: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/28.jpg)
Reduces Beta cell apoptosisunlike glimepiride
Metabolism. 2008;57:1038-1045.
MORE
EVIDENCESMORE
EVIDENCES
![Page 29: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/29.jpg)
Prolongs insulin free period
Diabetes Res Clin Pract. 2005;70:291-297.
While maintains HbA1c <7% for 14.5 years!!
![Page 30: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/30.jpg)
FACT: EFficacy & tolerAbility of DiamiCron MR60
at the dosage of 1.5 to 2 tablets at breakfast over
Bangladeshi Type 2 diabetic patients
![Page 31: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/31.jpg)
A clinical study conducted by Bangladeshi clinicians over
Bangladeshi type 2 diabetic patients
![Page 32: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/32.jpg)
Objective of the study
To observe efficacy and tolerability
of Diamicron MR60 at the dosage
of 1.5 to 2 tablets over Bangladeshi
type 2 diabetic patients
![Page 33: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/33.jpg)
Findings
![Page 34: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/34.jpg)
Patient characteristics
Characteristics (N= 359)Male (166) 166 (n)
Female (193) 193 (n)
Mean Age (279) 51 yrs ± 11
Mean Height (75) 1.5 m ± 0.6
Mean Weight (219) 64 kgs ± 9
Mean BMI (96) 26 ± 3
![Page 35: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/35.jpg)
Efficacy: Reduction of HbA1c (Total Patients)
5
5.5
6
6.5
7
7.5
8
8.5
9
Base line After 6 months
-1.9% HbA1c reduction within 6 months
-1.9%
n= 3598.9%
7.0%
![Page 36: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/36.jpg)
Tolerability
Only 1.0% hypoglycemia was found!!
Baseline After 6 months
Change
Weight (kgs)
63.7 63.3 -0.4
![Page 37: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/37.jpg)
Þ As per the FACT study, Diamicron MR
60 reduces HbA1c by -1.9% in 6
months at the dosage of 1.5 to 2
tablets
Þ With least hypoglycemia as well as no
weight gain
Findings of FACT study
![Page 38: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/38.jpg)
Clinical Evidences on use
of OAD in Ramadan
![Page 39: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/39.jpg)
Prof. Hajera MahtabProfessor EmeritusEx-Director Clinical Services, Research & AcademyDhaka, Bangladesh
Prof. Abdul Hamid ZargarProfessor & HeadDepartment of EndocrinologySK Institute of Medical SciencesSrinagar, India
Prof. Abdul BasitDirector & Head of the DepartmentBaqai Institute of Diabetology & EndocrinologyBaqai Medical UniversityKarachi, Pakistan
RESEARCH ANALYSIS
![Page 40: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/40.jpg)
Sulphonylureas in the management of type 2 diabetes during the fasting month of Ramadan
Among the 2nd generation SUs considering efficacy and safety,
which one is more suitable during Ramadan
Sulfonylureas as a first line used by majority of patients
Many of Muslim type 2 diabetic patients fast in Ramadan
Alteration of energy intake, physical activity & drug pattern
associated with greater risk of hypoglycemia & ketoacidosis
![Page 41: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/41.jpg)
Among the two once daily Sulphonylureas hypoglycemia is -50% less with Diamicron MR60 than glimepiride
Diamicron MR Glimepiride
![Page 42: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/42.jpg)
Diamicron MR60 is associated with less hypo and less CV events than glimepiride
![Page 43: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/43.jpg)
Objective:
To evaluate the efficacy & safety of Diamicron MR60 at the dosage of 1 tablet in Ramadan
Participating countries:
Bangladesh, India & Pakistan
![Page 44: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/44.jpg)
Prof. Hajera Mahtab BIHSProf. Zafar A Latif BIRDEMProf. Tofail Ahmed BIRDEMProf. M A Mannan DMCHProf. Md. Farid Uddin BSMMUDr. Saghir Abdur Rahim BIRDEMDr. Sarker M Saiful Islam MEDINOVADr. ABM Rahmatullah HCDP- JurainDr. Sufia Khatun NHN- Mirpur 10Dr. Umme Sadia Mili NHN- Darus SalamDr. Md. Wahiduzzaman NHN- Darus SalamDr. MA Sabur DAB- Khulna
THE RAMADAN STUDY GROUP- BANGLADESH
![Page 45: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/45.jpg)
Inclusion Criteria:
Newly diagnosed type 2 diabetic patients: start with 60 mg
Patients uncontrolled with 1 tablets of Diamicron MR/ Gliclazide 80/MR or 1 mg of Glimepiride: up-titrate to 60 mg Diamicron MR60
Patients well controlled on 60 mg of Diamicron MR60
Patients well controlled on 2 tablets of Gliclazide 80/MR or 2 mg of Glimepiride: switched to 60 mg of Diamicron MR60
THE RAMADAN STUDY
![Page 46: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/46.jpg)
Total number of patients:136 fasting type 2 diabetic (35 Bangladeshi+ 50 Indian+ 51 Pakistani)
Duration:90 days (45 before Ramadan+ 30 Ramadan+ 15 after Ramadan)
Result:- Around 1% (0.8%) HbA1c reduction within 3 months- 3.7% hypoglycemia before, 2.2% during & 1.5% after Ramadan
THE RAMADAN STUDY
![Page 47: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/47.jpg)
Conclusion:Diamicron MR60 maintains tight glycemic control, safely before, during & after Ramadan
![Page 48: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/48.jpg)
Objective:
To compare the incidence of symptomatic hypoglycemia in fasting Muslim patients with type 2 diabetes treated with DPP-4 inhibitor or SU during Ramadan.
Middle East
![Page 49: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/49.jpg)
Conclusion:Risk of hypoglycemia is lowest with Diamicron MR60, whereas double with glimepiride
![Page 50: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/50.jpg)
Þ IDF guideline (October’12) recommends
sulfonylurea to initiate treatment
irrespective of BMI
Þ But all sulfonylureas do not provide same
outcome
Þ Therefore, selection of sulfonylurea is a
major issue to be considered before
initiating treatment
Take home messages
![Page 51: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/51.jpg)
Þ As per the clinical evidences Diamicron MR
60
provides effective glycemic control
irrespective of BMI
with least risk of hypo & without weight
gain
significantly reduces vascular
complications
ensures cardiovascular protection unlike
glimepiride,
also better than metformin
preserves beta cell through anti-oxidant
properties
Take home messages
![Page 52: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/52.jpg)
Acknowledgement
• Prof. Md. Fariduddin• Asso. Prof. M A Hasanat• Dr. Mashfiqul Hasan• Dr. Yasmin Aktar• Sponsoring body
![Page 53: Gliclazide MR in the management of Type 2 Diabetes Mellitus](https://reader035.fdocument.pub/reader035/viewer/2022062405/55519f1ab4c9053c488b4a06/html5/thumbnails/53.jpg)
Thank you